Targeting LRRK2 mutations in Parkinson's disease

被引：1
|
作者：
Lesniak, Robert K. [1 ,2 ]
Nichols, Robert Jeremy [2 ]
Smith, Mark [1 ]
Montine, Thomas J. [2 ]
机构：
[1] Stanford Univ, Sarafan ChEM H, Med Chem Knowledge Ctr, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA
来源：
FUTURE MEDICINAL CHEMISTRY | 2022年 / 14卷 / 16期
关键词：
computational chemistry and molecular modeling; drug design; drug discovery; inflammation therapeutics; neurological therapeutics; pharmacokinetics; pharmacodynamics; rare diseases; IDENTIFICATION; METAANALYSIS; DISCOVERY; DESIGN;
D O I：
10.4155/fmc-2022-0102
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
[No abstract available]
引用
收藏
页码：1167 / 1170
页数：4
相关论文
共 50 条
  • [21] Screening for LRRK2 mutations in patients with Parkinson's disease in Russia:: identification of a novel LRRK2 variant
    Pchelina, S. N.
    Yakimovskii, A. F.
    Emelyanov, A. K.
    Ivanova, O. N.
    Schwarzman, A. L.
    Singleton, A. B.
    EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (07) : 692 - 696
  • [22] Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease
    Ito, Genta
    Utsunomiya-Tate, Naoko
    BIOMOLECULES, 2023, 13 (05)
  • [23] An overview of the worldwide distribution of LRRK2 mutations in Parkinson's disease
    El Otmani, Hicham
    Daghi, Mohamed
    Tahiri Jouti, Nadia
    Lesage, Suzanne
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2023, 13 (06) : 335 - 350
  • [24] MIBG scintigraphy in Parkinson's disease with and without LRRK2 mutations
    Masso, J. F. Marti
    Martinez, J. Ruiz
    Bolano, M. J.
    Gorostidi, A.
    Marras, C.
    de Munain, A. J. Lopez
    MOVEMENT DISORDERS, 2008, 23 (01) : S254 - S255
  • [25] Targeting LRRK2 in Parkinson's disease: an update on recent developments
    Chan, Sharon L.
    Tan, Eng-King
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (06) : 601 - 610
  • [26] LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting
    Xiong, Yulan
    Yu, Jianzhong
    TRENDS IN MOLECULAR MEDICINE, 2024, 30 (10) : 982 - 996
  • [27] LRRK2 Targeting Strategies as Potential Treatment of Parkinson's Disease
    Wojewska, Dominika Natalia
    Kortholt, Arjan
    BIOMOLECULES, 2021, 11 (08)
  • [28] Penetrance of LRRK2 mutations in familial Parkinson disease
    Nature Reviews Neurology, 2009, 5 (3) : 120 - 120
  • [29] Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition
    Doggett, Elizabeth A.
    Zhao, Jing
    Mork, Christina N.
    Hu, Dongmei
    Nichols, R. Jeremy
    JOURNAL OF NEUROCHEMISTRY, 2012, 120 (01) : 37 - 45
  • [30] LRRK2 kinase in Parkinson's disease
    Alessi, Dario R.
    Sammler, Esther
    SCIENCE, 2018, 360 (6384) : 36 - 37
12345